Save up to 90% on Zegerid with Coupons, Discount Cards & Patient Assistance Programs

Zegerid is the brand name for omeprazole/sodium bicarbonate and is available as an oral capsule and suspension.

Zegerid is available as a 20 mg omeprazole/1,100 mg sodium bicarbonate and 40 mg omeprazole/1,100 mg sodium bicarbonate oral capsule and 20 mg omeprazole/1,680 mg sodium bicarbonate and 40 mg omeprazole/1,680 mg sodium bicarbonate oral suspension.

Zegerid is a PPI and antacid that is used to treat:

• Stomach ulcer
• Duodenal (first part of small intestine) ulcer
• Heartburn and other symptoms related gastroesophageal reflux disease (GERD)
• Erosive esophagitis (inflammation of the esophagus) due to GERD
• Lower the risk of stomach bleeding in hospitalized people (suspension only)

Zegerid is a combination of two medications:

• Omeprazole is a proton pump inhibitor (PPI). It works by lowering the amount of acid made by your stomach
• Sodium bicarbonate is an antacid. This class of medication typically helps neutralize (or balance out) the acid in your stomach, which eases heartburn. But the purpose of sodium bicarbonate is to protect omeprazole from being broken down by stomach acid, not to treat symptoms of heartburn

Zegerid is dosed as follows:

• Prescription Zegerid
• The capsules contain either 20 mg or 40 mg of omeprazole and 1,100 mg of sodium bicarbonate. The oral suspension packets contain either 20 mg or 40 mg of omeprazole with 1,620 mg of sodium bicarbonate

Below, the dosing is in milligrams of omeprazole:

• Stomach ulcer: The typical dose is to take 40 mg by mouth once daily for 1 to 2 months.
• Duodenal ulcer: The typical dose is to take 20 mg by mouth once daily for 1 to 2 months
• GERD: The typical dose is to take 20 mg by mouth once daily for up to 1 month
• Erosive esophagitis: The typical dose is to take 20 mg by mouth once a day for 1 to 2 months. Depending on your condition, your provider might continue this treatment for longer than 2 months
• Lower the risk of stomach bleeding in hospitalized people (suspension only): The typical dose is to take 40 mg by mouth for the first dose, followed by 40 mg 6 to 8 hours later, and 40 mg once daily thereafter for a total treatment time of 14 days

OTC Zegerid

• Each capsule contains 20 mg of omeprazole and 1100 mg sodium bicarbonate
• Hearburn: The typical dose is to take 1 capsule by mouth daily for 2 weeks. If needed, you can repeat this treatment every 4 months

Konvomep (omeprazole / sodium bicarbonate):

• Stomach ulcer: The typical dose is to take 40 mg by mouth once daily for 1 to 2 months
• Lower the risk of stomach bleeding in hospitalized people: The typical dose is to take 40 mg by mouth for the first dose, followed by 40 mg 6 to 8 hours later, and 40 mg once daily thereafter for a total treatment time of 14 days

Zegerid is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you. You should not use this medication if you have

Common side effects of Zegerid:

• Headache
• Stomach pain
• Diarrhea
• Nausea
• Gas
• Vomiting

Serious side effects are rare with Zegerid. Contact your healthcare provider immediately if you experience any of the following.

• Severe diarrhea: watery diarrhea, fever, stomach pain that doesn’t go away
• Serious kidney problems: blood in your urine, urinating more or less than usual
• Severe skin reaction: fever, burning or stinging eyes, body aches, trouble swallowing, headache, chills, joint
• pain, red spots on the skin, rash, blisters
• Seriously low magnesium levels: irregular heart rate, muscle cramps, tremors, seizures

The following medications may interact with Zegerid:

• May affect plasma levels of antiretroviral drugs; use with atazanavir and nelfinavir is not recommended; if saquinavir is used with Zegerid, monitor for toxicity and consider saquinavir dose reduction
• May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, erlotinib, digoxin and mycophenolate mofetil). Patients treated with Zegerid and digoxin may need to be monitored for digoxin toxicity
• Combined inhibitor of CYP 2C19 and 3A4 may raise esomeprazole levels
• Clopidogrel: Zegerid decreases exposure to the active metabolite of clopidogrel
• May increase systemic exposure of cilostazol and an active metabolite. Consider dose reduction.
• Tacrolimus: Zegerid may increase serum levels of tacrolimus
• Methotrexate: Zegerid may increase serum levels of methotrexate

Salix Pharmaceuticals

There are no adequate and well-controlled studies with Zegerid in pregnant women. Zegerid should be used during
pregnancy only if the potential benefit justifies the potential risk to the fetus.

• Omeprazole/Sodium